Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Datopotamab deruxtecan - Daiichi Sankyo

Next Previous
Drug Profile

Datopotamab deruxtecan - Daiichi Sankyo

Alternative Names: Dato-DXd; DS 1062a; DS-1062; S-1062a; TROP2-directed ADC

Latest Information Update: 12 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer AstraZeneca; Daiichi Sankyo Company; Merck & Co
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration HER2 negative breast cancer; Non-small cell lung cancer
  • Phase III Triple negative breast cancer
  • Phase II Solid tumours
  • Phase I/II Gastric cancer; Urogenital cancer
  • No development reported Breast cancer

Most Recent Events

  • 10 Apr 2024 AstraZeneca in collaboration with Daiichi Sankyo plans a phase III TROPION-Lung10 trial for Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease, Combination therapy, First-line therapy) in Australia, Austria, Brazil, Canada, Germany, Hungary, Italy, Japan, Poland, South Korea, Spain, Taiwan, Turkey and UK in April 2024 (IV) (NCT06357533)
  • 09 Apr 2024 AstraZeneca plans a phase III TROPION-Lung14 trial for Non-small Cell Lung Cancer (Combination therapy, Late-stage disease, Metastatic disease, First line therapy, Recurrent) in Australia, China and Taiwan in May 2024 (PO) (NCT06350097)
  • 02 Apr 2024 Preregistration for HER2-negative-breast-cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) before April 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top